Indivior
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 1.1K
- Market Cap
- $1.6B
- Website
- http://indivior.com
- Introduction
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Transmucosal Drug Delivery Pipeline Report 2024 - Stages of
The 'Transmucosal Drug Delivery Pipeline Report 2024 Update' from ResearchAndMarkets.com offers comprehensive insights into pipeline products, clinical trials, and key companies involved in Transmucosal Drug Delivery.
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval
Indivior's PAS for SUBLOCADE granted Priority Review by FDA; PDUFA date set for February 7, 2025. PAS seeks label updates for alternative injection sites (thigh, buttock, back of arm) and rapid induction protocol, addressing unmet needs in OUD treatment.
Oral Thin Films Market Report Explores the Research, Outlook, Demand, Analysis 2024-2033
The oral thin films market is projected to reach $7.65 billion by 2028 with a CAGR of 13.6%, driven by specialty pharmaceuticals, precision medicine, and telemedicine. Key players include ZIM Laboratories, NAL Pharma, and Cure Pharmaceutical. The market is segmented by type, disease indication, and distribution channel.
© Copyright 2025. All Rights Reserved by MedPath